Vaxart

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vaxart reports solid Q1 earnings, progresses in vaccine development

Vaxart's Q1 2024 performance reflects financial stability and progress in vaccine development, particularly with positive Phase I trial results for their norovirus vaccine.
While the company faces challenges in funding, manufacturing, and program prioritization, opportunities lie in advancing COVID-19 vaccine trials and regulatory engagements.
By addressing concerns and leveraging opportunities effectively, Vaxart can strengthen its position in the vaccine market and drive future growth and innovation.

Vaxart reports strong Q3 revenue, advances in COVID and norovirus

Vaxart's Q3 2024 earnings call highlighted revenue from government contracts, progress in COVID, norovirus, and HPV programs, and promising trial data.
The company faces challenges in study enrollment, resource allocation, and regulatory compliance but remains open to collaborations and global vaccine development.
With a cash runway into 2026, Vaxart is well-positioned to leverage market demand for their oral pill vaccine candidates and drive future growth.
Strong performance, constructive FDA feedback, and market opportunities position Vaxart for continued success in vaccine development and partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in March 2004 and is headquartered in South San Francisco, CA.

Key Proposal #2 has received significant support, but additional votes are needed for approval

Vaxart Provides an Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022 to Vote by July 5, 2022, at 11:59 p.m. ET

Model will be used in Vaxart's Phase II Omicron Challenge Trial

Vaxart Announces Agreement with hVIVO to Develop World's First Human Omicron Challenge Model

Management to discuss progress on its programs, annual stockholders' meeting proposals

Vaxart to Host Investor Q&A Webcast

AstraZeneca

GlaxoSmithKline

Novartis

Sanofi

It depends on which subsector you're talking about.

What Could a Recession Mean for Healthcare Stocks?

Meeting adjourned to July 6, 2022 at 9:30 a.m. PT

Vaxart Announces Adjournment of Annual Meeting of Stockholders

Novavax

Both face significant risks in the coming quarters.

Better Buy: Novavax vs. Vaxart

Results provide additional support for the cross-reactivity of Vaxart's oral vaccine candidates

New Preclinical Data Demonstrate Two of Vaxart's COVID-19 Vaccine Candidates Protect Against Omicron

Inovio Pharmaceuticals

Stock Market Plunge: 2 Stocks to Avoid Right Now

Results support safety and immunogenicity of the vaccine candidate in the highly vulnerable elderly population

Vaxart Reports Positive Preliminary Data from the Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults

Amazon

Target

Vertex Pharmaceuticals

The stock market offers plenty of opportunities -- even during difficult times.

Market Dip: Here's How to Invest Safely

A preclinical study in hamsters showed both a decrease in infectious  virus and in transmission

Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 Transmission

Aurora Cannabis

Redfin

Select analysts foresee these once-popular stocks delivering huge gains for shareholders.

These 3 Former High-Flying Stocks Can Soar Up to 439%, According to Wall Street

The company still is far from the vaccine race finish line.

Can This 1 Thing Hurt Vaxart?

Data from COVID-19 Phase II study and norovirus Phase IB study are expected in 2022

Vaxart Provides Business Update and Reports First Quarter 2022 Financial Results

Bed Bath & Beyond

Netflix

Here are three stocks that have analysts running for the exit due to their declining or risky market prospects The post 3 Stocks That Have Analysts Running for the Exit appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn't matter if you have $500 in savings or $5 million.

3 Stocks That Have Analysts Running for the Exit

These two companies have been left in the dust. Is it too late for them?

2 Contenders in the Coronavirus Vaccine Market -- Are They Buys?

SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, will present at the World Vaccine Congress Washington 2022 in Washington, D.C. on Wednesday, April 20, 2022 at 3:55 p.m. ET.

Vaxart to Present at World Vaccine Congress Washington 2022 on April 20

Moderna

Their products could deliver major revenue over time.

3 Biotech Stocks That Could Help Make You a Fortune

Geron

Rivian Automotive

These stocks are expected to grow their sales by 26,519% to 100,236% over the next five years.

3 of the Fastest-Growing Stocks on the Planet Through 2026

Ocugen, Inc.

Select analysts foresee these coronavirus stocks rocketing higher by 246% to 355% over the next year.

3 COVID-19 Stocks With Monster Upside of Up to 355%, According to Wall Street

NEW YORK--(BUSINESS WIRE)-- #Class--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Vaxart, Inc. (NASDAQ: VXRT) on behalf of long-term stockholders following a class action complaint that was filed against Vaxart on August 24, 2020 with a Class Period from June 25, 2020 to July 25, 2020. Our investigation concerns whether the board of directors of Vaxart have breached their fiduciary duties to the company. The complaint alle

VAXART ALERT: Bragar Eagel & Squire, P.C. is Investigating Vaxart, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Is Vaxart the Next Moderna?

Bionano Genomics

Ginkgo Bioworks Holdings

These stocks are all about cutting-edge technology.

3 No-Brainer Stocks to Buy Right Now for Less Than $6

The past 12 months have been difficult for the biotech stock.

Is It Too Late to Buy Vaxart Stock?

These 19 Words From Vaxart Could Mean Trouble for Vaccine Rivals

News for Vaxart Stock (VXRT)